Skip to main content

Table 3 EUA (US FDA) and approved anti-SARS-CoV-2 therapeutic antibodies

From: A critical overview of current progress for COVID-19: development of vaccines, antiviralĀ drugs, and therapeutic antibodies

Antibody

US EUA date

Approved

Pause to use

Manufacturer

References

Bamlanivimab

11/09/2020

ā€“

U.S. (04/16/2021)

Eli Lily and Company

[11, 12]

REGEN-COV (Casirivimabā€‰+ā€‰Imdevimab)

11/21/2020

EU, UK, Japan

U.S. (01/24/2022)

Regeneron pharmaceuticals

[13,14,15,16]

Bamlanivimabā€‰+ā€‰Etesevimab

02/09/2021

ā€“

U.S. (01/24/2022)

Eli Lily and Company

[11, 241]

Xevudy (Sotrovimab)

05/26/2021

EU, UK

U.S. (03/30/2022)

GlaxoSmithKline plc and Vir Biotechnology, Inc

[196]

Evusheld (Cilgavimabā€‰+ā€‰Tixagevimab)

12/02/2021

EU, UK

ā€“

AstraZeneca

[204]

Bebtelovimab

02/11/2022

ā€“

ā€“

Eli Lily and Company

[242]

Regkirona

(Regdanvimab)

ā€“

EU, South Korea

ā€“

Celltrion HealthCare

[243]

  1. EU European Union, EUA Emergency Use Authorization